Abstract:Background: Antibody-dendrimer conjugates have the potential to improve the targeting and release of chemotherapeutic drugs at the tumor site while reducing adverse side effects caused by drug accumulation in healthy tissues. In this study, trastuzumab (TMAB), which binds to human epidermal growth factor receptor 2 (HER2), was used as a targeting agent in a TMAB-polyamidoamine (PAMAM) conjugate carrying paclitaxel (PTX) specifically to cells overexpressing HER2.Methods: TMAB was covalently linked to a PAMAM dendrimer via bifunctional polyethylene glycol (PEG). PTX was conjugated to PAMAM using succinic anhydride as a cross-linker, yielding TMAB-PEG-PAMAM-PTX. Dynamic light scattering and transmission electron microscopy were used to characterize the conjugates. The cellular uptake and in vivo biodistribution were studied by fluorescence microscopy, flow cytometry, and Carestream In Vivo FX, respectively.Results: Nuclear magnetic resonance spectroscopy demonstrated that PEG, PTX, fluorescein isothiocyanate, and cyanine7 were conjugated to PAMAM. Ultraviolet-visible spectroscopy and sodium dodecyl sulfate polyacrylamide gel electrophoresis demonstrated that TMAB was conjugated to PEG-PAMAM. Dynamic light scattering and transmission electron microscopy measurements revealed that the different conjugates ranged in size between 10 and 35 nm and had a spherical shape. In vitro cellular uptake demonstrated that the TMAB-conjugated PAMAM was taken up by HER2-overexpressing BT474 cells more efficiently than MCF-7 cells that expressed lower levels of HER2. Co-localization experiments indicated that TMAB-conjugated PAMAM was located in the cytoplasm. The in vitro cytotoxicity of TMAB-conjugated PAMAM was lower than free PTX due to the slow release of PTX from the conjugate. In vivo targeting further demonstrated that TMAB-conjugated PAMAM accumulated in the BT474 tumor model more efficiently than non-conjugated PAMAM.Conclusion: TMAB can serve as an effective targeting agent, and the TMAB-conjugated PAMAM can be exploited as a potential targeted chemotherapeutic drug delivery system for tumors that overexpress HER2.

Peptide-Conjugated Pamam for Targeted Doxorubicin Delivery to Transferrin Receptor Overexpressed Tumors

Plasmid Porf-Htrail and Doxorubicin Co-Delivery Targeting to Tumor Using Peptide-Conjugated Polyamidoamine Dendrimer

New Transferrin Receptor-Targeted Peptide–Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity

A Ph‐responsive Nanoparticle Delivery System Containing Dihydralazine and Doxorubicin‐based Prodrug for Enhancing Antitumor Efficacy

Targeted Multifunctional Redox-Sensitive Micelle Co-Delivery of DNA and Doxorubicin for the Treatment of Breast Cancer

Peptide-conjugated PEGylated PAMAM as a highly affinitive nanocarrier towards HER2-overexpressing cancer cells

Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style.

Construction and Evaluation of PAMAM–DOX Conjugates with Superior Tumor Recognition and Intracellular Acid-Triggered Drug Release Properties

Dextran-doxorubicin Prodrug Nanoparticles Conjugated with CD147 Monoclonal Antibody for Targeted Drug Delivery in Hepatoma Therapy.

Targeted and Ph-Responsive Delivery of Doxorubicin to Cancer Cells Using Multifunctional Dendrimer-Modified Multi-Walled Carbon Nanotubes

Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer <i>in vivo</i>

Targeted Delivery of Polyamidoamine-Paclitaxel Conjugate Functionalized with Anti-Human Epidermal Growth Factor Receptor 2 Trastuzumab

Targeted Delivery of Doxorubicin Using Transferrin-Conjugated Carbon Dots for Cancer Therapy

Tumor-targeted and stimulus-responsive polymeric prodrug nanoparticles to enhance the anticancer therapeutic efficacy of doxorubicin

Peptide-mediated Cationic Micelles Drug-Delivery System Applied on a VEGFR3-overexpressed Tumor.

Stimuli-responsive PEGylated Prodrugs for Targeted Doxorubicin Delivery

Antitumor Efficacy of Doxorubicin Encapsulated Within PEGylated Poly(amidoamine) Dendrimers

Tumor-specific Delivery of Doxorubicin Through Conjugation of Ph-Responsive Peptide for Overcoming Drug Resistance in Cancer

Tpe-Based Peptide Micelles For Targeted Tumor Therapy And Apoptosis Monitoring

Enhancing Cancer Targeting and Anticancer Activity by A Stimulus-Sensitive Multifunctional Polymer-Drug Conjugate

Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer